The estimated Net Worth of Jason A Okazaki is at least $1.06 Milion dollars as of 2 August 2024. Mr Okazaki owns over 981 units of Assembly Biosciences Inc stock worth over $262,455 and over the last 5 years he sold ASMB stock worth over $94,740. In addition, he makes $703,273 as Chief Operating Officer at Assembly Biosciences Inc.
Mr has made over 12 trades of the Assembly Biosciences Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 981 units of ASMB stock worth $13,960 on 2 August 2024.
The largest trade he's ever made was selling 11,827 units of Assembly Biosciences Inc stock on 2 August 2023 worth over $12,891. On average, Mr trades about 2,319 units every 50 days since 2020. As of 2 August 2024 he still owns at least 15,101 units of Assembly Biosciences Inc stock.
You can see the complete history of Mr Okazaki stock trades at the bottom of the page.
Jason A. Okazaki is the Chief Operating Officer at Assembly Biosciences Inc.
As the Chief Operating Officer of Assembly Biosciences Inc, the total compensation of Mr Okazaki at Assembly Biosciences Inc is $703,273. There are 5 executives at Assembly Biosciences Inc getting paid more, with John McHutchison having the highest compensation of $7,007,210.
Mr Okazaki is 45, he's been the Chief Operating Officer of Assembly Biosciences Inc since . There are 17 older and 2 younger executives at Assembly Biosciences Inc. The oldest executive at Assembly Biosciences Inc is Alan Lewis, 74, who is the Independent Director.
Jason's mailing address filed with the SEC is C/O ASSEMBLY BIOSCIENCES, INC., TWO TOWER PLACE, 7TH FLOOR, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 10 years, insiders at Assembly Biosciences Inc have traded over $1,523,622 worth of Assembly Biosciences Inc stock and bought 1,245,980 units worth $1,060,065 . The most active insiders traders include Sciences, Inc. Gilead, Myron Z Holubiak oraz Helen Susan Kim. On average, Assembly Biosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $389,399. The most recent stock trade was executed by Nicole S White on 2 August 2024, trading 785 units of ASMB stock currently worth $11,171.
assembly biosciences, inc. (nasdaq: asmb) is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and novel oral live biotherapeutics for disorders associated with the microbiome. assembly is developing two innovative platform programs: an hbv program advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. assembly’s hbv program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic hbv. the company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current good manufacturing practices and a patent-pending delivery system, gemicel®, which allows for targeted ora
Assembly Biosciences Inc executives and other stock owners filed with the SEC include: